8E8

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/II clinical trial for neuroendocrine tumors indications; ELC-201 for the treatment of various injectable solid tumors; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy for the treatment of solid tumors. Elicera Therapeutics AB (publ) has collaboration with the Josep Carreras Leukemia Research Institute to provide iTANK platform.